See the DrugPatentWatch profile for canakinumab

Based on the information available, there is currently no estimated timeline for the approval and availability of biosimilars for Canakinumab, a interleukin-1 beta inhibitor drug used to treat certain inflammatory diseases.

Canakinumab is marketed under the brand name Ilaris and is developed by Novartis. The drug was approved by the US Food and Drug Administration (FDA) in 2009. Biosimilars are follow-on versions of already approved biologic drugs, and they are typically less expensive than the original drug.

According to DrugPatentWatch.com, the patent for Canakinumab is set to expire in 2024 in the United States, which would open the door for the development and approval of biosimilars. However, the exact timeline for the approval of Canakinumab biosimilars is not yet clear.

It's important to note that the development and approval of biosimilars can be a complex and time-consuming process. The FDA evaluates biosimilars using the same standards as for the original drug, including clinical studies to demonstrate that the biosimilar is highly similar to the original drug and that there are no clinically meaningful differences in safety, purity, and potency.

In summary, based on the available information, the estimated timeline for the approval and availability of Canakinumab biosimilars is not yet clear, but it is expected that the first biosimilars could be approved and become available in the market after the patent expiration of Canakinumab in 2024.

Sources:

* [DrugPatentWatch.com](https://www.DrugPatentWatch.com)
* US Food and Drug Administration (FDA)
* Novartis

Note: The information provided is based on publicly available data and is intended to be used for informational purposes only. It should not be considered as medical or legal advice.